Refractive ErrorNCT00708643
Clinical Performance of a New Daily Disposable Contact Lens Worn in an Established Contact Lens Wearing Population
A study testing Habitual Silicone Hydrogel Contact Lens and narafilcon A in people with Refractive Error and Myopia, run by Johnson & Johnson Vision Care, Inc. at 1 site in Canada.
Trial summary
This study seeks to evaluate the clinical and subjective performance of a new daily disposable soft contact lens. Read more about this study
- Who is it for?
- Ages 17 years and older
- Conditions the study is for
- Refractive Error, Myopia
- What is being tested?
- Habitual Silicone Hydrogel Contact Lens and narafilcon A
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteCanada
- Study dates
- Jun 2008to Sep 2008
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 17 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- They are of legal age (17 years) and capacity to volunteer.
- They understand their rights as a research subject and are willing to sign a Statement of Informed Consent.
- They are willing and able to follow the protocol.
- They would be expected to attain at least 6/9 (20/30) in each eye with the study lenses.
- They are able to wear contact lenses with a back vertex power of -1.00 to -6.00DS.
- They have a maximum of 1.00D of refractive astigmatism (i.e. ≤ 1.00 DC).
- They have successfully worn contact lenses within six months of starting the study.
Who cannot join
- They have an ocular disorder which would normally contra-indicate contact lens wear.
- They have a systemic disorder which would normally contra-indicate contact lens wear.
- They are using any topical medication such as eye drops or ointment.
- They are aphakic.
- They have had corneal refractive surgery.
- They have any corneal distortion resulting from previous hard or rigid lens wear or has keratoconus.
Show all 11Show fewer
- They are pregnant or lactating.
- They have grade 2 or greater of any of the following ocular surface signs: corneal oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear.
- They have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. HIV).
- They have diabetes.
- They have taken part in any other clinical trial or research, within two weeks prior to starting this study.
Trial locations and contacts
1 site in 1 country.
About this study
This study seeks to evaluate the clinical and subjective performance of a new daily disposable soft contact lens.
- Conditions
- Refractive Error, Myopia
- Being tested
- Habitual Silicone Hydrogel Contact Lens, narafilcon A
- Medical subject headings
- Refractive Errors, Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Habitual Silicone Hydrogel Contact LensDevice
contact lens
narafilcon ADevice
contact lens
| Study group | Role | What they receive |
|---|---|---|
| Habitual silicone hydrogel | Active comparator | Habitual contact lens wear. Receives: Device: Habitual Silicone Hydrogel Contact Lens |
| narafilcon A | Experimental | Silicone hydrogel daily disposable contact lens Receives: Device: narafilcon A |
What is being measured
The primary outcome is the main question the study is designed to answer.
Limbal Hyperemia
Measures the redness of the limbal region of the eye on a scale of 0 to 100 grade with 0=none and 100=severe. The analysis is the average grade over all time frames.
Measured: At 2 weeks and 4 weeks
Lens Comfort
Rating of lens comfort by rating agreement to the following statement:
"The lenses I am wearing are comfortable."
Rating using the following scale:
1=strongly agree, 2=agree, 3=neutral, 4=disagree, 5=strongly disagree. The rating is averaged over all time frames.
Measured: At 3,7,10,13,17,21,24, and 27 days
Upper Lid Margin Staining
Measures the trauma to tissue that lines the margin of the inside of the upper eyelid on a 0 to 3 scale, with 0=none to 3=severe. The analysis is the average grade over all time frames.
Measured: At 2 weeks and 4 weeks.
Secondary outcomes (3)
Tarsal Roughness
Measures the amount of roughness to the tissue of the inside upper and lower eyelid on a scale of 0 to 100 with 0=none and 100=severe. The analysis is the average grade over all time frames.
Measured: At 2 weeks and 4 weeks
Tarsal Hyperemia
Measures the amount of redness to the tissue of the inside upper and lower eyelid using a 0 to 100 scale with 0=none and 100=severe.
Measured: At 2 weeks and 4 weeks.
Corneal Staining
A measure of corneal abrasion using a 0 to 100 scale with 0=none, 25=micropunctate, 50=macropunctate, 75=coalescence, 100=patch. The analysis is the average grade over all time frames.
Measured: At 2 weeks and 4 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jul 2008 (estimated)
- Study startJun 2008
- Primary completionSep 2008
- Study completionSep 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Refractive ErrorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Manchester
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00708643
- Sponsor's protocol ID
- CR-0803
- Status last verified
- May 2015
- First submitted
- 27 Jun 2008
- Last updated
- 21 May 2015
- Results posted
- Yes, on ClinicalTrials.gov